ArticleScientific reports2025
NOX4 serves as a pan-cancer prognostic biomarker and therapeutic target in tumorigenesis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- NADPH oxidases in immunometabolism and disease pathology: mechanistic networks, pollutant triggers, and therapeutic frontiers.Cellular & molecular immunology · 2026Review
- Size-Dependent Differences in the Effects of Low-Dose Selenium Nanoparticles on Chronic Thioacetamide Toxicosis Accompanying HCC Progression in Mice.Biological trace element research · 2026Article
- Research progress on the expression characteristics, biological functions, and therapeutic potential of NOX4 in malignant tumors: a functional perspective.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- NOX4 suppresses malignant progression in prostate adenocarcinoma and functions as a potential diagnostic biomarker.Translational andrology and urology · 2026Article
- ASCL2 contributes to clinical assessments of breast cancer and mediates tumor progression via the interaction with CLDN3.Scientific reports · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NADPH oxidase 4 (NOX4) is a key regulator of intracellular reactive oxygen species (ROS) and plays a critical role in tumorigenesis and cancer progression. It contributes to cancer cell transformation, proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT). To elucidate the molecular mechanisms underlying NOX4-mediated tumorigenesis, we performed a comprehensive pan-cancer bioinformatics analysis, integrating data from The Cancer Genome Atlas (TCGA), and validated our findings with in vitro experiments. We systematically analyzed NOX4 expression patterns across various cancer types and explored the correlations between NOX4 expression and patient survival, immune infiltration, tumor mutational burden (TMB), and microsatellite instability (MSI). In vitro assays, including Wound healing, Transwell, and CCK-8 assays, were conducted to validate the biological functions of NOX4 in breast cancer cells. Pan-cancer analysis revealed that NOX4 is significantly upregulated in various cancers, including breast cancer. Elevated NOX4 expression is associated with poor patient prognosis, immune cell infiltration, TMB, and MSI. Functional experiments confirmed that downregulation of NOX4 can inhibit the proliferation and metastasis of breast cancer cells. Our pan-cancer analysis provides valuable insights into the role of NOX4 in tumorigenesis. These results highlight NOX4 as a promising biomarker for prognosis and a potential therapeutic target for anti-tumor treatments across multiple cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.